Article Dans Une Revue Kidney International Reports Année : 2022

Safety, Efficacy and Relapse of Nirmatrelvir-Ritonavir in Kidney Transplant Recipients Infected with SARS-CoV-2

Résumé

Introduction - The efficacy of nirmatrelvir-ritonavir (NR; Paxlovid, Pfizer, New York, NY) to decrease the risk of progression to severe COVID-19 in high-risk patients has been demonstrated. However, evidence in infected kidney transplant recipients (KTRs) is lacking. Moreover, NR has significant and potentially harmful interactions with calcineurin inhibitors (CNIs). Methods - In this single-center retrospective study, we included all KTRs treated with NR from April 28 to June 3, 2022. A standard management strategy of CNI dose adaptation (discontinuation of tacrolimus 12 hours before the start of NR and administration of 20% of the cyclosporine dose) and laboratory follow-up was applied. Results - A total of 14 patients were included. Compared with day-0 (day before NR initiation), day-7 plasma creatinine concentrations and SARS-CoV-2 viral loads were similar ( = 0.866) and decreased ( = 0.002), respectively. CNI trough concentrations at the end of the treatment were satisfactory, nonetheless, with high individual variability. After a median follow-up time of 34 days, no death or viral pneumonia were observed. Nevertheless, 2 patients experienced early SARS-CoV-2 infection relapses (at day-10 and day-21) associated with an increase in SARS-CoV-2 viral loads. Conclusion - NR can be used in KTRs but requires a strict protocol of drug adaptation. We observed 2 cases of early relapse after NR treatment that need further investigations.

Fichier principal
Vignette du fichier
Devresse.pdf (841.82 Ko) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

hal-03789825 , version 1 (27-09-2022)
hal-03789825 , version 2 (05-10-2022)

Licence

Identifiants

Citer

Arnaud Devresse, Sébastien Briol, Julien de Greef, Florian Lemaitre, Lidvine Boland, et al.. Safety, Efficacy and Relapse of Nirmatrelvir-Ritonavir in Kidney Transplant Recipients Infected with SARS-CoV-2. Kidney International Reports, 2022, 7 (11), pp.2356-2363. ⟨10.1016/j.ekir.2022.08.026⟩. ⟨hal-03789825v2⟩
297 Consultations
279 Téléchargements

Altmetric

Partager

  • More